NRP1-4 (Neuropilin 1-4) is a highly potent, specific small molecule inhibitor of VEGF-A binding to neuropilin 1 (NRP1) with IC50 of 0.598 nM, reduces calcium and sodium currents through binding to NRP1 and inhibits the effects of VEGF-A.
NRP1-4 (Neuropilin 1-4) is more potent than EG00229 (Cat# PC-42701).
NRP1-4 (Neuropilin 1-4) binds to the serotonin 5-HT7A receptor and histamine H1 receptor with higher affinity compare to NRP1/VEGF-R2, does not have off-target liability at opioid receptors.
NRP1-4 (Neuropilin 1-4) blocks VEGF A–induced increase in dorsal root ganglia excitability.
NRP1-4 (Neuropilin 1-4) attenuates VEGF A-mediated increases in sodium currents.
Inhibition of VEGF A-mediated increase in sodium currents by Neuropilin 1-4 is through NaV1.7.
NRP1-4 (Neuropilin 1-4) blocks VEGF-A-mediated increase in N-type calcium currents.
NRP1-4 (Neuropilin 1-4) reverses VEGF A-mediated increase in N-type calcium currents, prevents VEGF-A–mediated increase in CaV2.2 and NaV1.7 surface expression in rat DRG neurons.
NRP1-4 (Neuropilin 1-4) reverses VEGFA-mediated increase in frequency of spontaneous excitatory postsynaptic currents in the lumbar dorsal horn, NRP1-4 (Neuropilin 1-4) reverses mechanical allodynia following spared nerve injury in rats.